Judd Moul reviews the history of the U.S. Preventative Services Task Force screening guidelines and highlights the US trends and patterns of disparities in cancer mortality among U.S. counties from 1980 to 2014. Full Video online at UroToday July 12 2018. Our transcript, August 7 2018, is from the section Moul calls “the bottom line.”
“There have been no randomized trials of prostate cancer screening for black men. The only 2 randomized screening trials (one in Europe, one in the USA) included very few African American men. And one of the things that really bothers me … Why hasn’t there been … a true randomized trial focusing on African American men, to answer the question … “Is it beneficial to screen for prostate cancer in this high risk group? What is the proper age to initiate screening for African American men? Is it 40, 45, 50, or is it 55? We don’t know that, it’s only speculation. Continue reading “Screening for Prostate Cancer in African American Men – Judd Moul”
Discovery could lead to treatments for this condition, cachexia
PSA Rising August 5, 2018 (NEW YORK, NY, June 6, 2018)—About one-third of all cancer deaths are caused not by the cancer itself but by cachexia—a debilitating muscle-wasting syndrome that affects an estimated 80 percent of advanced cancer patients. Cachexia is linked to reduced tolerance for cancer therapy, poor quality of life, and accelerated death, but there are no effective treatments and its cause is still largely unknown.
A new multicenter, internal study led by researchers at Columbia University Irving Medical Center suggests that an overload of zinc in patients’ muscles may be the culprit. The findings, published online June 6 in Nature Medicine, could pave the way for the development of drugs to treat or prevent muscle wasting in advanced cancer patients. Continue reading “Excess Zinc in Muscles Contributes to Wasting Syndrome in Cancer”
Analysis of Prostate Tumors Reveals Clues to Cancer’s Aggressiveness Sequencing finds genetic errors common in metastatic tumors
PSA Rising August 4 2018. A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease.
Using genetic sequencing, scientists revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The multicenter study lays the foundation for finding new ways to treat prostate cancer, particularly for the most aggressive forms of the disease.
A non-surgical solution for enlarged prostates, used in Europe, now FDA approved in USA
Physicians at UC San Diego Health are now offering prostate artery embolization (PAE) as a new treatment option for men with benign prostatic hyperplasia (BPH), or an enlarged prostate. The minimally invasive procedure is an alternative to surgery, with no hospital stay, little operative pain and lower cost.
August 3, PSA Rising. African American men are more likely to develop prostate cancer than men of any other race and the disease is often more aggressive when diagnosed.
Now, African American touched by prostate cancer are being asked to join an ambitious study to find out why African-American men are at higher risk for developing more aggressive forms of prostate cancer and why they are more likely to die from it.